Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections

University Hospital, Strasbourg, France200 enrolled

Overview

Recent international recommendations suggest the use of carbapenem rather than cefepime in this situation, but with a low level of evidence, given the few existing studies. As cefepime is a less broad-spectrum antibiotic than carbapenems, its use would limit the selection of multidrug-resistant bacteria.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Bacteremia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Adult patient (≥18 years of age) * managed within a study center for high-grade cephalosporinase-producing bacteremia * Not objecting to the reuse of their health data for scientific research purposes. Exclusion Criteria: * Patient who has expressed opposition to the reuse of their data for scientific research purposes. * Resistance to Cefepime or carbapenems * Multiple bacteremia * Treatment with a molecule other than Cefepime or carbapenem.

Locations (1)

Service des maladies infectieuses et tropicales - CHU de Strasbourg - France

Strasbourg, France

Outcomes

Primary Outcomes

Hospital mortality

Time frame: 30 days after infection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.